（肝癌干细胞）CD13isatherapeutictargetinhumanlivercancerstemcells.pdfVIP

Research article CD13 is a therapeutic target in human liver cancer stem cells 1,2 1,3 3 3 4 Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Masahisa Ohkuma, 1 1 1 1 1 Ho Min Kim, Hirofumi Akita, Daisuke Takiuchi, Hisanori Hatano, Hiroaki Nagano, 5 1 1 Graham F. Barnard, Yuichiro Doki, and Masaki Mori 1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. 2Excellent Young Researchers Overseas Visit Program, Japan Society for the Promotion of Science (JSPS), Tokyo, Japan. 3 Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Oita, Japan. 4 Department of Surgery, Jikei University School of Medicine, Tokyo, Japan. 5 Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA. Cancer stem cells (CSCs) are generally dormant or slowly cycling tumor cells that have the ability to recon- stitute tumors. They are thought to be involved in tumor resistance to chemo/radiation therapy and tumor relapse and progression. However, neither their existence nor their identity within many cancers has been well defined. Here, we have demonstrated that CD13 is a marker for semiquiescent CSCs in human liver cancer cell lines and clinical samples and that targeting these cells might provide a way to treat this disease. CD13+ cells predominated i